Effects of Therapeutic and Supratherapeutic Doses of Siponimod (BAF312), a Selective S1P1,5 Receptor Modulator, on Cardiac Repolarization: A Thorough QTc (TQT) Study

Trial Profile

Effects of Therapeutic and Supratherapeutic Doses of Siponimod (BAF312), a Selective S1P1,5 Receptor Modulator, on Cardiac Repolarization: A Thorough QTc (TQT) Study

Completed
Phase of Trial: Phase I

Latest Information Update: 27 Oct 2015

At a glance

  • Drugs Siponimod (Primary) ; Moxifloxacin
  • Indications Multiple sclerosis
  • Focus Adverse reactions
  • Sponsors Novartis Pharma A.G.
  • Most Recent Events

    • 27 Oct 2015 Results published in the Clinical Therapeutics
    • 29 Apr 2014 Results presented at the 66th Annual Meeting of the American Academy of Neurology.
    • 28 Apr 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top